Martin Fan
Stock Analyst at Wedbush
(4.92)
# 191
Out of 4,993 analysts
60
Total ratings
84.1%
Success rate
81.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Fan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRAX First Tracks Biotherapeutics | Reiterated: Buy | $60 → $70 | $38.60 | +81.35% | 4 | Sep 3, 2026 | |
| RNAC Cartesian Therapeutics | Reiterated: Buy | $38 | $8.03 | +373.23% | 7 | Aug 18, 2026 | |
| IMUX Immunic | Initiated Coverage: Buy | $45 | $10.62 | +323.73% | 1 | Aug 17, 2026 | |
| NKTR Nektar Therapeutics | Reiterated: Hold | $80 | $67.10 | +19.23% | 4 | Aug 14, 2026 | |
| GETY Getty Images Holdings | Rated: Hold | n/a | $0.2232 | - | 1 | Aug 12, 2026 | |
| VOR Vor Biopharma | Reiterated: Hold | $18 → $27 | $21.40 | +26.17% | 4 | Aug 12, 2026 | |
| ZURA Zura Bio | Reiterated: Buy | $15 → $22 | $4.46 | +393.27% | 4 | Aug 12, 2026 | |
| ORKA Oruka Therapeutics | Reiterated: Buy | $45 → $165 | $94.96 | +73.76% | 5 | Aug 11, 2026 | |
| SANA Sana Biotechnology | Reiterated: Buy | $7 | $3.10 | +125.81% | 5 | Aug 11, 2026 | |
| IMA ImageneBio | Reiterated: Sell | $2 | $4.89 | -59.10% | 4 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $8.61 | +364.58% | 3 | May 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $2.53 | +176.68% | 4 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $5.50 | +81.82% | 7 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $46 | $52.77 | -12.83% | 1 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $31.50 | +42.86% | 4 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 → $45 | $55.20 | n/a | 2 | Aug 7, 2025 |
First Tracks Biotherapeutics
Sep 3, 2026
Reiterated: Buy
Price Target: $60 → $70
Current: $38.60
Upside: +81.35%
Cartesian Therapeutics
Aug 18, 2026
Reiterated: Buy
Price Target: $38
Current: $8.03
Upside: +373.23%
Immunic
Aug 17, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $10.62
Upside: +323.73%
Nektar Therapeutics
Aug 14, 2026
Reiterated: Hold
Price Target: $80
Current: $67.10
Upside: +19.23%
Getty Images Holdings
Aug 12, 2026
Rated: Hold
Price Target: n/a
Current: $0.2232
Upside: -
Vor Biopharma
Aug 12, 2026
Reiterated: Hold
Price Target: $18 → $27
Current: $21.40
Upside: +26.17%
Zura Bio
Aug 12, 2026
Reiterated: Buy
Price Target: $15 → $22
Current: $4.46
Upside: +393.27%
Oruka Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $45 → $165
Current: $94.96
Upside: +73.76%
Sana Biotechnology
Aug 11, 2026
Reiterated: Buy
Price Target: $7
Current: $3.10
Upside: +125.81%
ImageneBio
Aug 6, 2026
Reiterated: Sell
Price Target: $2
Current: $4.89
Upside: -59.10%
May 21, 2026
Reiterated: Buy
Price Target: $40
Current: $8.61
Upside: +364.58%
May 14, 2026
Reiterated: Buy
Price Target: $7
Current: $2.53
Upside: +176.68%
May 8, 2026
Reiterated: Buy
Price Target: $10
Current: $5.50
Upside: +81.82%
Feb 26, 2026
Reiterated: Buy
Price Target: $46
Current: $52.77
Upside: -12.83%
Dec 22, 2025
Reiterated: Buy
Price Target: $45
Current: $31.50
Upside: +42.86%
Aug 7, 2025
Reiterated: Buy
Price Target: $40 → $45
Current: $55.20
Upside: n/a